Five-year survival data suggest brentuximab vedotin potentially curative in some hodgkin lymphoma patients with limited treatment options



Phase II trial suggests therapy should be standard of care for patients facing relapsed or treatment-resistant Hodgkin lymphoma.



Source link

sticket2

Would you like to get the test?

This entry was posted in Uncategorized. Bookmark the permalink.